Taken together, these results demonstrate that endosomal recycling inhibitors can modulate the levels of the nuclear receptors ER-α and AR, and that they may be effective at treating certain forms of breast cancer when used in combination with hormone receptor antagonists. Here, ESR1 is linked to breast carcinoma.